Cytochrome P450 eicosanoids in hypertension and renal disease
about
Cytochrome P450 ω-Hydroxylases in Inflammation and CancerInterlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids.Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient MiceInteraction of the renin angiotensin and cox systems in the kidney.The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation.Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat.Identification of potential candidate genes for hypertensive nephropathy based on gene expression profile.Associations of Whole Blood n-3 and n-6 Polyunsaturated Fatty Acids with Blood Pressure in Children and Adolescents - Results from the IDEFICS/I.Family Cohort20-Hydroxyeicosatetraenoic Acid (20-HETE) Modulates Canonical Transient Receptor Potential-6 (TRPC6) Channels in PodocytesMolecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic TargetSclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling.Microsomal cytochrome P450 as a target for drug discovery and repurposing.Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.Contribution of PPARα/β/γ, AP-1, importin-α3, and RXRα to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against hypotension, tachycardia, and inflammation in a rat model of septic shock.Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR.Cytochrome P450-2E1 is involved in aging-related kidney damage in mice through increased nitroxidative stress.Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in Saccharomyces cerevisiae.Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.GPCRS IN CONTEXT: SEXUAL DIMORPHISM IN THE CARDIOVASCULAR SYSTEM.Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.GPR75 Identified as the First 20-HETE Receptor: A Chemokine Receptor Adopted by a New Family.Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.Is renal tubular cadmium toxicity clinically relevant?Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1Cerebral Autoregulation in Hypertension and Ischemic Stroke: A Mini Review
P2860
Q26800210-4FE25EC5-6C3F-4FE7-9344-7EF1869D6A1CQ27333891-10CF9CCE-7262-4007-AF03-47B8BE9C0D4AQ28398028-4EB8024E-25B9-4D2D-9BD5-EC1DB12A42E4Q30276943-F20B8F4D-A5A4-461F-A1B6-8ACF1782A98CQ33567867-94A08AAB-2A7D-47C5-ABA6-0D1C63709393Q35138567-09D6A13E-DAF0-4E00-AEC9-DA6BB8C27C55Q36166668-349E1E21-FAC9-4EF8-8CCC-D7456D805B8CQ36180513-C8293381-0C2D-4EE0-8E1B-D1C027A1E157Q37218316-A44528F1-5FCA-4600-A065-A72D2195B129Q37340856-E5627F34-8679-49FF-B2E9-75CFFC56B4ADQ37731230-318FC791-A0FF-486D-92E3-D976D5220DECQ38795694-B7BB22B9-9C18-4D15-B306-E7F315C9A52FQ39000644-78DF6A84-617A-483D-BFCD-0C91FD3EEB56Q39431317-A066B376-7A47-4E82-B0BB-60CEFDE77DB1Q40792305-FF53BF5F-4C90-4E13-AEC7-94E076A8E5E0Q41439393-1E402722-3365-41FF-A7E1-DDC44D5595ABQ41648482-9F7D76AE-269D-42C1-868B-5D5F568FC305Q42151348-F31C726A-1A68-4F12-AE0D-EF1A6490DC04Q47658696-2B36C3AA-30EA-4F01-A71E-85A474934B82Q47824410-57781BC3-DF77-46EE-8BA8-314B8B040B4BQ47911043-2CD4F477-3692-4D62-92F5-4CF0A2EDA0C5Q49929077-2352DE2A-ADBF-4F61-B376-39CA18E615C3Q50081720-68B0EE79-B019-422E-8FD5-E7BE019AC658Q51741240-85CAA1E2-3CF1-4A50-86BF-2FD40DF4AE60Q53265857-4083CFAA-28D9-4E8F-97FF-687B5FD0088BQ53507984-BB5FD017-C373-43FA-AE98-0AA3924365D6Q57053849-C0E52E69-423D-4CD8-BCAB-A5C515CE1B07Q57139017-9B7112F4-093B-4C7B-B1A3-94AE8DBF974DQ57211205-4C43ED44-A5E7-45F8-A9A6-0795FB3FC394
P2860
Cytochrome P450 eicosanoids in hypertension and renal disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cytochrome P450 eicosanoids in hypertension and renal disease
@ast
Cytochrome P450 eicosanoids in hypertension and renal disease
@en
Cytochrome P450 eicosanoids in hypertension and renal disease
@nl
type
label
Cytochrome P450 eicosanoids in hypertension and renal disease
@ast
Cytochrome P450 eicosanoids in hypertension and renal disease
@en
Cytochrome P450 eicosanoids in hypertension and renal disease
@nl
prefLabel
Cytochrome P450 eicosanoids in hypertension and renal disease
@ast
Cytochrome P450 eicosanoids in hypertension and renal disease
@en
Cytochrome P450 eicosanoids in hypertension and renal disease
@nl
P2093
P2860
P921
P3181
P1476
Cytochrome P450 eicosanoids in hypertension and renal disease
@en
P2093
Richard J Roman
Yoshikazu Muroya
P2860
P3181
P356
10.1097/MNH.0000000000000088
P407
P5008
P577
2015-01-01T00:00:00Z